(VB-111) VBL Therapeutics Provides Year End 2016 Corporate Update Ovarian Cancer and Us OVARIAN CANCER and US Ovarian Cancer and Us

Blog Archives: Nov 2004 - present

#ovariancancers



Special items: Ovarian Cancer and Us blog best viewed in Firefox

Search This Blog

Monday, January 09, 2017

(VB-111) VBL Therapeutics Provides Year End 2016 Corporate Update



press release

  Founded in 2000, VBL is based in Or-Yehuda, Israel. 

 

| Source: VBL Therapeutics
TEL AVIV, Israel, Jan. 09, 2017 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ:VBLT), provides corporate update and reviews anticipated highlights for 2017.
  • Following positive EOP2 meeting on VB-111 in ovarian cancer, VBL plans to launch a Phase 3 trial of VB-111 in Ovarian Cancer during the second half of 2017.
  • Interim analysis in the GLOBE pivotal study is expected in mid-2017, with top-line data expected in early 2018.
  • VBL's novel immune-oncology target to be disclosed during 1H 2017....
 VBL website

0 comments :

Post a Comment

Your comments?